Skip to main content
Clinical Trials/KCT0007504
KCT0007504
Recruiting
未知

The Postoperative Radiotherapy after Breast Conserving Surgery or Mastectomy in N1 Breast Cancer Patients: A Prospective, Multicenter, Phase III Clinical Trial (PORT-N1)

Seoul National University Hospital0 sites1,106 target enrollmentTBD
ConditionsNeoplasms

Overview

Phase
未知
Intervention
Not specified
Conditions
Neoplasms
Sponsor
Seoul National University Hospital
Enrollment
1106
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional Study
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients aged 19 years or older.
  • \-A female patient who underwent breast\-conserving surgery or mastectomy for invasive breast cancer.
  • \-Patient with stage pN1 after surgery on histopathologic examination.
  • \*\* However, if mastectomy was performed, 5 or more nodes should be resected in the case of 1 positive node, and axillary lymph node dissection (ALND) should be performed in case of 2 or 3 positive nodes.
  • \-Patients undergoing or planning to undergo hormone therapy in the case of hormone receptor positive.
  • \-Patients who have received or are expected to undergo targeted therapy in the case of HER\-2 positive.
  • \-Patients with Eastern Cooperative Oncology Group (ECOG) Scale 0\-2\.
  • \-Patients who agreed to participate in the study.

Exclusion Criteria

  • \-Patients who have received prior \[neoadjuvant] chemotherapy.
  • \-Patients receiving radiation therapy for salvage or palliative purposes.
  • \-Patients with stage T4\.
  • \-Patients with ipsilateral supraclavicular and internal mammary lymph node metastases or distant metastases.
  • \-Male breast cancer patient.
  • \-Patients who have previously received radiation therapy to the ipsilateral breast or supraclavicular region.
  • \-Patients having a history of cancer other than thyroid cancer, cervical carcinoma in situ, or skin cancer.
  • \-Patients diagnosed with ductal breast carcinoma in situ, lobular carcinoma in situ, phyllodes, metaplastic cancer, or benign tumors based on histological diagnosis.

Outcomes

Primary Outcomes

Not specified

Similar Trials